| Name | Title | Contact Details |
|---|---|---|
Emily Taylor |
Chief Financial and Operating Officer | Profile |
Ronald Levine |
Vice President Enterprise Sales | Profile |
Victoria Noble |
Chief Marketing Officer | Profile |
Heidi Anderson Hupe |
President and Chief Growth Officer | Profile |
Planned Parenthood is the leading provider of reproductive health care in the country. At Planned Parenthood of Orange and San Bernardino Counties, we fight for the fundamental right of all individuals to determine their own destiny.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.
Seaside Healthcare, our mission is to improve the lives of our patients and their communities through outcome-based, cost-effective mental-health services delivered with dignity and respect.
iMedicor, Inc. is a national provider of comprehensive secure communications solutions for the medical and dental communities. iMedicor offers dentists, general practitioners, specialized doctors and other healthcare professionals the use of a secure, HIPAA-compliant communications network that addresses current federal standards for security and interoperability. iMedicor also serves as one of the country's leading Meaningful Use consultants to assist doctors and dentists with conversion from paper to electronic health records (EHRs) and qualify under Medicare and Medicaid guidelines for Federal Incentive Funding.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.